Table 1. Demographic and clinical characteristics of subjects.
| Group | HCs | Drug responder (n = 34) | Drug-nonresponder (n = 16) | ||
| Before | After | Before | After | ||
| ESR (mm/hour) | 13(4–19) | 53(28–120)* | 21(7–65)* # | 69(15–105)* | 60(30–95)* |
| CRP (mg/dl) | 4.2(0.3–6.2) | 31.6(0.61–141)* | 7.6(1.66–40.9)* # | 18.9(3.8–104)* | 16.4(0.8–93.7)* |
| RF (IU/ml) | 14(0.4–27) | 319.4(0.11–1270)* | 58 (3.37–501)* # | 265.7(25.8–1440)* | 163(2.57–1020)* |
| RF (+/−) | NA | 31/3 | 9/25 | 15/1 | 14/2 |
| Anti-CCP (IU/ml) | 4.32(0.24–6.29) | 547(0.67–2476)* | 51.3(5.4–798)* # | 652(35.6–2778)* | 359(21.9–2250)* |
| Anti-CCP (+/−) | NA | 33/1 | 7/24 | 16/0 | 15/1 |
| DAS28 | NA | 6.39(3.76–9.85)* | 3.38(1.65–5.07)* # | 7.15(3.9–10.12)* | 5.27(3.74–9.96)* |
Data shown are median (range) of each group of subjects. RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive Protein; CCP: cyclic citrullinated peptide; DAS28: Disease Activity Score in 28 joints; NA: not applicable;
*P<0.05 vs. HCs;
#
P<0.05 vs. baseline values.